iBio, Inc. develops AI-driven precision antibody therapies for cardiometabolic, obesity and cardiopulmonary diseases. Company news commonly covers pipeline updates for IBIO-600, a long-acting anti-myostatin monoclonal antibody, and IBIO-610, an Activin E antibody candidate, along with preclinical body-composition data and regulatory clearances tied to early clinical development.
Recurring updates also include iBio's antibody-discovery approach, including computational biology and epitope-steering, as well as financial results, capital financing, investor-conference presentations and board or committee changes.
iBio (NASDAQ: IBIO) announced it will participate in the Wells Fargo 21st Annual Healthcare Conference in Boston, held September 8–10, 2026. CEO and Chief Scientific Officer Martin Brenner will join a fireside chat on September 8 at 4:30 p.m. ET, available via livestream and 90-day webcast replay on iBio’s Investor Relations site.
CFO Felipe Duran will join Dr. Brenner for one-on-one investor meetings during the conference, which can be requested by contacting the company’s investor relations email. iBio is a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, cancer, and other hard-to-treat conditions.
iBio (NASDAQ: IBIO) reported fiscal year 2026 results and a corporate update, highlighted by its transition to a clinical-stage company with the Phase 1 trial of IBIO-600, a long-acting anti-myostatin antibody. The single ascending dose phase dosed 31 of 32 participants across four cohorts with no safety findings that prevented dose escalation, and iBio is preparing multiple ascending dose escalation.
The company advanced obesity and cardiometabolic candidates IBIO-610 into IND-enabling studies and IBIO-800 into IND-enabling development, and in-licensed AstralBio’s amylin receptor antibody program. iBio closed an August 2025 public offering with potential gross proceeds up to $100 million and a $26 million private placement in January 2026, and entered a $100 million at-the-market facility. Revenues were $0.1 million versus $0.4 million in 2025; R&D expenses rose to $19.6 million, G&A was $10.6 million, and a $5.0 million intangible impairment was recorded. Net loss was $33.0 million, and cash, cash equivalents and debt securities totaled $88.0 million at June 30, 2026.
iBio (NASDAQ: IBIO) appointed endocrinologist Molly Carr, M.D. as Chief Medical Officer to lead global clinical strategy, medical affairs and regulatory initiatives as it advances its long-acting antibody pipeline for obesity and cardiometabolic diseases toward late-stage development.
According to iBio, Dr. Carr brings over 30 years of clinical, academic and biopharmaceutical experience, including senior roles at Eli Lilly, GlaxoSmithKline, CSL Behring and Wyeth, and leadership of Lilly’s insulin and glucagon franchise and the Phase 3 program for once-weekly insulin efsitora. iBio highlighted that her expertise aligns with its obesity, muscle biology and cardiometabolic programs, including IBIO-600 and IBIO-610. The company also granted Dr. Carr options to purchase 430,000 shares of common stock as an inducement award, with a $1.40 exercise price, 10-year term, time-based vesting through quarterly installments after a one-year cliff, and accelerated vesting upon certain change-in-control or involuntary termination events.
iBio (NASDAQ: IBIO) reported preclinical obese non-human primate data for IBIO-610, a potential first-in-class Activin E antibody for obesity. A single dose reduced active Activin E by 98% at week 4 and 97% at week 8, with levels below assay limits.
Combined with semaglutide, IBIO-610 increased visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone, suggesting fat-selective weight loss potential and infrequent dosing. Full results will be presented at the 2026 EASD Annual Meeting in Milan.
iBio (NASDAQ: IBIO) announced participation in two upcoming healthcare investor conferences. CEO/CSO Martin Brenner and CFO Felipe Duran will present and hold investor meetings.
The events include the Jefferies Global Healthcare Conference on June 4, 2026, in New York and the Leerink Partners Therapeutics Forum on July 14–15, 2026, in Boston.
iBio (NASDAQ: IBIO) dosed the first participant in its Phase 1 trial of IBIO-600, becoming a clinical-stage company. IBIO-600 is a long-acting anti-myostatin/GDF11 monoclonal antibody being tested in adults with overweight and obesity for safety, tolerability, PK/PD, and exploratory body composition effects.
iBio (NASDAQ:IBIO) reported Q3 FY2026 results and a broad pipeline update. The company received Australian regulatory and ethics clearance to start a first-in-human Phase 1 trial of obesity candidate IBIO-600, with initial dosing in overweight and obese adults expected in Q2 calendar 2026.
iBio expanded its pipeline into PH-HFpEF with a selective bispecific antibody and reported new obese NHP data for IBIO-610, showing 6.7% visceral fat and 5.2% total fat mass reductions in a small, non-powered study. Q3 revenue was zero; R&D rose to $3.3M and G&A to $5.1M, including a $2.5M IBIO-101 impairment. Cash, equivalents and debt securities were $74.8M at March 31, 2026, plus $17M gross from Q4 FY2026 warrant exercises, extending the cash runway into Q4 FY2028.
iBio (NASDAQ:IBIO) appointed Elizabeth Stoner, M.D., M.S., to its Board of Directors and to the Compensation Committee on May 8, 2026, concurrent with the departure of director Eef Schimmelpennink.
Dr. Stoner brings over 35 years of R&D leadership, industry and board experience and will support iBio as it begins its first human clinical trial for IBIO-610, IBIO-600 and other assets.
iBio (NASDAQ: IBIO) received Clinical Trial Notification acknowledgement from Australia’s TGA and Human Research Ethics Committee approval to start a Phase 1 first-in-human study of IBIO-600. The randomized, double-blind, placebo-controlled single ascending dose trial targets overweight and obese adults.
First participant dosing is expected in 2Q 2026. IBIO-600 targets myostatin and GDF11 to preserve lean mass, is engineered for infrequent dosing (potentially 2–4 times per year) and showed a 40–52 day half-life and up to 5.1% lean-mass gains in non-human primates, with accompanying fat-mass reductions in preclinical studies.
iBio (NASDAQ:IBIO) will host a corporate update call on March 17, 2026 at 4:00 p.m. ET to discuss expansion into pulmonary hypertension associated with HFpEF (PH-HFpEF) and its engineered selective bispecific antibody program.
iBio expects to select an optimized bispecific development candidate in Q3 2026 before starting IND-enabling activities.